Definium Therapeutics, Inc. Total Liabilities
Definium Therapeutics, Inc. total liabilities. Based on the latest financial reports, Definium Therapeutics, Inc. (DFTX) has total liabilities worth $194.22 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check DFTX financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Definium Therapeutics, Inc. (2015–2025)
Total liabilities of Definium Therapeutics, Inc. from 2015 to 2025. This chart illustrates how Definium Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore Definium Therapeutics, Inc. long-term investment allocation to see how much of total assets are deployed in long-term investments.
Definium Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Definium Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Novanta Inc
F:1GSN
|
Germany | €704.34 Million |
|
Kilroy Realty Corp
NYSE:KRC
|
USA | $5.18 Billion |
|
Union Bank of Taiwan Pref
TW:2838A
|
Taiwan | NT$980.49 Billion |
|
Mega Or
TA:MGOR
|
Israel | ILA7.50 Billion |
|
Beijing Compass Technology Develop
SHE:300803
|
China | CN¥15.90 Billion |
|
Emmi AG
SW:EMMN
|
Switzerland | CHF2.26 Billion |
|
Gitlab Inc
NASDAQ:GTLB
|
USA | $686.50 Million |
|
Gentex Corporation
NASDAQ:GNTX
|
USA | $476.85 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Definium Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see DFTX asset base.
Liquidity & Leverage Metrics
Definium Therapeutics, Inc. Total Liabilities Ratios Explained
Definium Therapeutics, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Definium Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Definium Therapeutics, Inc. (2015–2025)
The table below shows the annual total liabilities of Definium Therapeutics, Inc. from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $107.77 Million | +77.54% |
| 2024-12-31 | $60.70 Million | +30.81% |
| 2023-12-31 | $46.41 Million | +143.27% |
| 2022-12-31 | $19.08 Million | +54.61% |
| 2021-12-31 | $12.34 Million | +118.33% |
| 2020-12-31 | $5.65 Million | +2740.31% |
| 2019-12-31 | $198.96K | +2317.58% |
| 2018-12-31 | $8.23K | -89.77% |
| 2017-12-31 | $80.44K | +6.59% |
| 2016-12-31 | $75.47K | +908.28% |
| 2015-12-31 | $7.49K | -- |
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a cli… Read more